JP2010540648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540648A5 JP2010540648A5 JP2010528062A JP2010528062A JP2010540648A5 JP 2010540648 A5 JP2010540648 A5 JP 2010540648A5 JP 2010528062 A JP2010528062 A JP 2010528062A JP 2010528062 A JP2010528062 A JP 2010528062A JP 2010540648 A5 JP2010540648 A5 JP 2010540648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- opioid antagonist
- constipation
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 239000003401 opiate antagonist Substances 0.000 claims 16
- 206010010774 Constipation Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 230000002496 gastric effect Effects 0.000 claims 6
- 206010028813 Nausea Diseases 0.000 claims 5
- -1 morphinan compound Chemical class 0.000 claims 5
- 230000008693 nausea Effects 0.000 claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical group C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000003467 chloride channel stimulating agent Substances 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- JVLBPIPGETUEET-GAAHOAFPSA-O methylnaltrexone Chemical compound C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 JVLBPIPGETUEET-GAAHOAFPSA-O 0.000 claims 3
- 229960002921 methylnaltrexone Drugs 0.000 claims 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 3
- 229960003086 naltrexone Drugs 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- PCSQOABIHJXZMR-MGQKVWQSSA-O (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O PCSQOABIHJXZMR-MGQKVWQSSA-O 0.000 claims 2
- HJDWPCLBBHHTIG-NNJWZEOZSA-O (4r,7s,7ar,12bs)-3-methyl-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7,9-diol Chemical compound O([C@H]1[C@H](C=CC23)O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O HJDWPCLBBHHTIG-NNJWZEOZSA-O 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 claims 2
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 claims 2
- 229960000345 lubiprostone Drugs 0.000 claims 2
- 239000002623 mu opiate receptor antagonist Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000024798 heartburn Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97665207P | 2007-10-01 | 2007-10-01 | |
| US60/976,652 | 2007-10-01 | ||
| PCT/US2008/078229 WO2009045985A1 (en) | 2007-10-01 | 2008-09-30 | Treatment of drug-induced nausea with opioid antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208895A Division JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540648A JP2010540648A (ja) | 2010-12-24 |
| JP2010540648A5 true JP2010540648A5 (enExample) | 2012-11-22 |
| JP5905198B2 JP5905198B2 (ja) | 2016-04-20 |
Family
ID=40526634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528062A Expired - Fee Related JP5905198B2 (ja) | 2007-10-01 | 2008-09-30 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
| JP2014208895A Pending JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208895A Pending JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP5905198B2 (enExample) |
| WO (1) | WO2009045985A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| WO2012148002A1 (en) * | 2011-04-27 | 2012-11-01 | Sucampo Ag | Method for modulating ion transporter |
| WO2013161973A1 (en) * | 2012-04-23 | 2013-10-31 | Sucampo Ag | Method for treating irritable bowel syndrome with diarrhea |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| MXPA02005335A (es) * | 1999-11-29 | 2003-01-28 | Adolor Corp | Metodos y composiciones novedosos que incluyen opioides y antagonistas de los mismos. |
| JP2006522817A (ja) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
| HRP20150037T4 (hr) * | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| US20070010450A1 (en) * | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| CN101311170B (zh) * | 2007-05-25 | 2010-09-15 | 中国中化股份有限公司 | 取代嘧啶醚类化合物及其应用 |
-
2008
- 2008-09-30 WO PCT/US2008/078229 patent/WO2009045985A1/en not_active Ceased
- 2008-09-30 JP JP2010528062A patent/JP5905198B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-10 JP JP2014208895A patent/JP2015028074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2235375C (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist | |
| UA93543C2 (ru) | Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон | |
| JP2015514743A5 (enExample) | ||
| WO2007005716A2 (en) | Methods of treatment and compositions for use thereof | |
| JP6279547B2 (ja) | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 | |
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| WO2006020930A3 (en) | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | |
| JP2011137020A5 (enExample) | ||
| JP2007508325A5 (enExample) | ||
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| CA2569742A1 (en) | Opioids for the treatment of the restless leg syndrome | |
| MY144471A (en) | Use of oxycodone for treating visceral pain | |
| JP2013505260A5 (enExample) | ||
| JP5905198B2 (ja) | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 | |
| US20120245193A1 (en) | PERIPHERIALLY ACTING μ OPIOID ANTAGONISTS | |
| HK1210959A1 (en) | Use of opioid receptor antagonist for gastrointestinal tract disorders | |
| JP2017526719A5 (enExample) | ||
| WO2006053012A3 (en) | Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria | |
| RU2003135201A (ru) | Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами | |
| Aurilio et al. | Opioid induced constipation | |
| McRae et al. | Opioid equivalency: a review | |
| HK1173956A (en) | Use of opioid receptor antagonist for gastrointestinal tract disorders | |
| Lim et al. | The Effects on Pain Relief of Intraarticular Tramadol and Neostigmine after Knee Arthroscopic Surgery. | |
| Galloway et al. | Opioid-induced bowel dysfunction. |